Trial Profile
A Phase Ib, Open-label, Single Center, Non-randomized Study for Safety and Efficacy of TQB2450 Combined With Anlotinib in Patients With Advanced Mutation Positive Non-Small Cell Lung Cancer
Status:
Recruiting
Phase of Trial:
Phase I
Latest Information Update: 04 Aug 2021
Price :
$35
*
At a glance
- Drugs Benmelstobart (Primary) ; Catequentinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Chia Tai Tianqing Pharmaceutical Group
- 31 Jan 2021 Results presented at the 2020 World Conference on Lung Cancer
- 13 Aug 2019 Status changed from not yet recruiting to recruiting.
- 13 Aug 2019 Status changed from not yet recruiting to recruiting.